Name (Synonyms) | Correlation | |
---|---|---|
drug1650 | Norovirus Bivalent (GI.1 / GII.4) Vaccine(middle) Wiki | 0.71 |
drug1649 | Norovirus Bivalent (GI.1 / GII.4) Vaccine(low) Wiki | 0.71 |
drug2024 | Random Donor Plasma Wiki | 0.71 |
drug1648 | Norovirus Bivalent (GI.1 / GII.4) Vaccine(high) Wiki | 0.71 |
drug151 | Aluminum adjuvant Wiki | 0.71 |
drug290 | BI 894999 Wiki | 0.41 |
drug2381 | Supportive Care Wiki | 0.41 |
drug1219 | Interferon Beta-1A Wiki | 0.35 |
drug1645 | Normal saline Wiki | 0.32 |
drug698 | DAS181 Wiki | 0.29 |
drug1270 | Ivermectin Wiki | 0.17 |
drug1086 | Hydroxychloroquine Wiki | 0.07 |
There are 2 clinical trials
Currently, no effective treatments are available for the COVID-19 pandemic, which is related to more than 70,000 deaths all over the world. Scientists and Researchers are working on many aspects of treatment options for the development of vaccination and medication to combat this life-threatening problem. Convalescent plasma from recovered COVID-19 patients contains antibodies against COVID-19 which may be beneficial to severely sick COVID019 infected patients. We have planned a randomized controlled trial to assess the efficacy of this therapy in COVID-19 infected sick patients. We will collect up to 500 ml Convalescent Plasma from the COVID-19 infected recovered patient after 14 days of clinical and radiological recovery with two consecutive COVID-19 negative tests by PCR. We will further test the sample from the collected plasma for COVID-19 specific antibodies and their titer. This plasma will be frozen and sent to the treating center (MAMC). 200-600 ml of convalescent plasma will be transfused to patients who fit the eligibility criteria and are randomized to the convalescent plasma group. This will be done in severely sick patients. Data will be collected for the benefit and adverse events related to convalescent plasma transfusion.
On 11th of March 2020, WHO characterized COVID-19 infection as a Pandemic. After the COVID-19 infection is declared as a Pandemic there was an outburst regarding COVID-19 Research. The Research interest led to registration of Interventional and Observational studies world wide. There are constant efforts by Health care workers to seek information regarding the Interventional and Observational studies which can help in decision making regarding effective handling of COVID-19 infected patients. It is also important to track on the happenings in various frontiers of COVID-19 Research in view of historical interest and clinical relevance. This Observational Cross sectional study aims to explore the completed Researches in WHO-compliant registries to understand the trends of COVID-19 Research. This study aims to get a birds eye view of ongoing COVID-19 Research scenario worldwide. This study results can directly benefit the worldwide Academicians and Health Care Professionals to understand the ongoing COVID-19 Research trends.
Description: To understand the geographical distribution of the interventional studies after 11th of March 2020.
Measure: Geographical distribution of the interventional studies after 11th of March 2020. Time: 15th of August 2020Description: To understand the geographical distribution of the Observational studies after 11th of March 2020.
Measure: Geographical distribution of the Observational studies after 11th of March 2020. Time: 15th of August 2020Description: To understand the monthly Research study completion rate as per geographic distribution of the Research.
Measure: Monthly Research study completion rate as per geographic distribution of the Research. Time: 15th of August 2020Description: To understand the statistical correlation of the interventional studies Research with developed, developing and under developed countries.
Measure: Statistical correlation of the interventional studies Research with developed, developing and under developed countries. Time: 15th of August 2020Description: To understand the statistical correlation of the observational studies Research with developed, developing and under developed countries.
Measure: Statistical correlation of the observational studies Research with developed, developing and under developed countries. Time: 15th of August 2020Description: To understand the statistical correlation of the Drug based interventional studies Research with developed, developing and under developed countries.
Measure: Statistical correlation of the Drug based interventional studies Research with developed, developing and under developed countries. Time: 15th of August 2020Description: To understand the statistical correlation of the Diagnostic test based interventional studies Research with developed, developing and under developed countries.
Measure: Statistical correlation of the Diagnostic test based interventional studies Research with developed, developing and under developed countries. Time: 15th of August 2020Description: To understand the statistical correlation of the Device based interventional studies Research with developed, developing and under developed countries.
Measure: Statistical correlation of the Device based interventional studies Research with developed, developing and under developed countries. Time: 15th of August 2020